Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant
- PMID: 20029384
- DOI: 10.1038/tpj.2009.65
Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant
Abstract
D2 blockade has been implicated in having a central role in antipsychotic response. However, treatment refractoriness, in spite of complete D2 blockade, as well as the efficacy of clozapine (CLZ) in a portion of this patient population, indicates the involvement of other factors as well. Several lines of evidence suggest a role for D3. Furthermore, an earlier meta-analysis by Jönsson et al. (2003) (n=233) suggested a role for genetic variation in the D3 gene. Relevant to this study, Jönsson et al. found the Ser allele of the D3 serine-to-glycine substitution at amino acid position 9 (Ser9Gly) polymorphism to be associated with worse CLZ response compared with the Gly allele. In this study, we attempt to validate these findings by performing a meta-analysis in a much larger sample (n=758). Eight other variants were also tested in our own sample to explore the possible effect of other regions of the gene. We report a negative but consistent trend across individual studies in our meta-analysis for the DRD3 Ser allele and poor CLZ response. A possible minor role for this single-nucleotide polymorphism cannot be disregarded, as our sample size may have been insufficient. Other DRD3 variants and haplotypes of possible interest were also identified for replication in future studies.
Similar articles
-
The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.Mol Psychiatry. 1998 Jan;3(1):72-5. doi: 10.1038/sj.mp.4000288. Mol Psychiatry. 1998. PMID: 9491816
-
Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients.Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):56-60. doi: 10.1002/ajmg.b.30770. Am J Med Genet B Neuropsychiatr Genet. 2009. PMID: 18449897
-
Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.Psychopharmacology (Berl). 2005 Aug;181(1):179-87. doi: 10.1007/s00213-005-2223-5. Epub 2005 Oct 15. Psychopharmacology (Berl). 2005. PMID: 15830237
-
[Pharmacogenetics and treatment response in schizophrenia].Encephale. 2007 Dec;33(6):954-64. doi: 10.1016/j.encep.2007.01.004. Epub 2007 Sep 4. Encephale. 2007. PMID: 18789788 Review. French.
-
Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.Pharmacogenomics. 2004 Sep;5(6):691-8. doi: 10.1517/14622416.5.6.691. Pharmacogenomics. 2004. PMID: 15335289 Review.
Cited by
-
The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism.Eur J Clin Pharmacol. 2024 Feb 29. doi: 10.1007/s00228-024-03658-w. Online ahead of print. Eur J Clin Pharmacol. 2024. PMID: 38421437
-
Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine.Front Pharmacol. 2023 May 9;14:1182393. doi: 10.3389/fphar.2023.1182393. eCollection 2023. Front Pharmacol. 2023. PMID: 37229261 Free PMC article.
-
The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.J Pers Med. 2023 Mar 4;13(3):471. doi: 10.3390/jpm13030471. J Pers Med. 2023. PMID: 36983653 Free PMC article. Review.
-
Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives.Front Pharmacol. 2022 Oct 12;13:1005702. doi: 10.3389/fphar.2022.1005702. eCollection 2022. Front Pharmacol. 2022. PMID: 36313375 Free PMC article. Review.
-
Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.Methods Mol Biol. 2022;2547:389-425. doi: 10.1007/978-1-0716-2573-6_14. Methods Mol Biol. 2022. PMID: 36068471
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
